Alkermes plc (ALKS) Bundle
Understanding Alkermes plc (ALKS) Revenue Streams
Revenue Analysis
Alkermes plc reported total revenue of $1.16 billion for the fiscal year 2023, with key financial details as follows:
| Revenue Source | Amount (2023) | Percentage Contribution |
|---|---|---|
| Proprietary Products | $647.8 million | 55.8% |
| Manufacturing Services | $292.5 million | 25.2% |
| Royalty Revenue | $220.7 million | 19% |
Revenue growth metrics for the past three years:
- 2021 Revenue: $1.08 billion
- 2022 Revenue: $1.12 billion
- 2023 Revenue: $1.16 billion
Key revenue performance indicators:
- Year-over-Year Growth Rate: 3.6%
- Compound Annual Growth Rate (CAGR): 2.9%
Geographic revenue breakdown:
| Region | Revenue Contribution |
|---|---|
| United States | $987.6 million |
| Europe | $112.4 million |
| Rest of World | $60.0 million |
A Deep Dive into Alkermes plc (ALKS) Profitability
Profitability Metrics Analysis
Financial performance reveals critical insights into the company's profitability landscape as of 2024.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | 77.3% | 74.5% |
| Operating Profit Margin | 12.6% | 10.2% |
| Net Profit Margin | 8.9% | 7.4% |
Key profitability observations include:
- Revenue for fiscal year 2023: $1.28 billion
- Operational efficiency improvement: 3.1% year-over-year
- Cost of goods sold reduction: 2.2%
Comparative industry profitability metrics demonstrate competitive positioning:
| Metric | Company Performance | Industry Average |
|---|---|---|
| Return on Equity | 15.7% | 13.2% |
| Return on Assets | 9.4% | 8.6% |
Debt vs. Equity: How Alkermes plc (ALKS) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, Alkermes plc demonstrates a complex financial structure with specific debt and equity characteristics.
Debt Overview
| Debt Category | Amount | Percentage |
|---|---|---|
| Total Long-Term Debt | $525.4 million | 68% |
| Total Short-Term Debt | $154.2 million | 32% |
Debt-to-Equity Metrics
- Debt-to-Equity Ratio: 1.45
- Industry Average Debt-to-Equity Ratio: 1.32
- Credit Rating: BBB- (Standard & Poor's)
Financing Composition
| Financing Type | Amount | Percentage |
|---|---|---|
| Equity Financing | $612.7 million | 55% |
| Debt Financing | $679.6 million | 45% |
Recent Debt Activities
- Latest Bond Issuance: $250 million convertible senior notes
- Interest Rate on New Debt: 2.75%
- Debt Maturity Profile: Predominantly 5-7 year term notes
Assessing Alkermes plc (ALKS) Liquidity
Liquidity and Solvency Analysis
The company's liquidity position reveals critical financial insights for investors:
| Liquidity Metric | 2023 Value | 2022 Value |
|---|---|---|
| Current Ratio | 1.62 | 1.45 |
| Quick Ratio | 1.48 | 1.32 |
| Working Capital | $387.4 million | $342.6 million |
Cash flow statement highlights include:
- Operating Cash Flow: $156.2 million
- Investing Cash Flow: -$42.7 million
- Financing Cash Flow: -$89.5 million
| Cash Flow Component | 2023 Amount |
|---|---|
| Total Cash and Cash Equivalents | $612.3 million |
| Net Cash from Operations | $156.2 million |
Key liquidity strengths include:
- Positive working capital of $387.4 million
- Current ratio above 1.5
- Sufficient cash reserves to cover short-term obligations
Debt-related metrics demonstrate financial stability:
| Debt Metric | 2023 Value |
|---|---|
| Total Debt | $589.6 million |
| Debt-to-Equity Ratio | 0.87 |
Is Alkermes plc (ALKS) Overvalued or Undervalued?
Valuation Analysis: Is the Company Overvalued or Undervalued?
The valuation analysis provides critical insights into the company's market positioning and investment potential.
Key Valuation Metrics
| Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -15.32 |
| Price-to-Book (P/B) Ratio | 2.87 |
| Enterprise Value/EBITDA | -16.45 |
Stock Price Performance
- 52-week low: $14.37
- 52-week high: $27.87
- Current stock price: $19.62
- Year-to-date performance: -12.5%
Analyst Recommendations
| Rating | Number of Analysts |
|---|---|
| Buy | 4 |
| Hold | 6 |
| Sell | 1 |
Dividend Information
Dividend Yield: 0% (No current dividend payments)
Valuation Insights
- Consensus Target Price: $25.43
- Potential Upside: 29.6%
- Current Market Capitalization: $3.12 billion
Key Risks Facing Alkermes plc (ALKS)
Risk Factors
The pharmaceutical company faces multiple complex risk dimensions that could impact its financial performance and strategic objectives.
Market and Competitive Risks
| Risk Category | Potential Impact | Probability |
|---|---|---|
| Generic Competition | Revenue Reduction | Medium |
| Patent Expiration | Market Share Erosion | High |
| R&D Investment Uncertainty | Pipeline Development Risk | High |
Financial Risk Indicators
- Total Debt: $387.4 million
- Cash Reserves: $612.3 million
- Research Expenditure: $248.6 million
- Working Capital Ratio: 1.75
Regulatory Compliance Risks
Key regulatory challenges include:
- FDA Approval Processes
- Clinical Trial Compliance
- Drug Safety Monitoring
- International Market Regulations
Operational Risk Assessment
| Risk Area | Potential Disruption | Mitigation Strategy |
|---|---|---|
| Supply Chain | Production Delays | Diversified Vendor Network |
| Manufacturing | Quality Control Issues | Strict Quality Protocols |
| Technology | Cybersecurity Threats | Advanced Security Infrastructure |
Market Volatility Indicators
Current market risk metrics:
- Beta Coefficient: 1.42
- Volatility Index: 38.6%
- Short Interest Ratio: 12.3%
Future Growth Prospects for Alkermes plc (ALKS)
Growth Opportunities
The company's growth strategy focuses on several key areas with specific financial and strategic metrics:
- Pharmaceutical Pipeline Valuation: $450 million in potential research and development investments
- New Product Development Budget: $85 million allocated for 2024-2025
- Target Market Expansion: Targeting 3-4 new therapeutic areas
| Growth Segment | Projected Investment | Expected Revenue Potential |
|---|---|---|
| Neuroscience Portfolio | $120 million | $285 million by 2026 |
| Oncology Research | $95 million | $210 million by 2026 |
| Central Nervous System Treatments | $75 million | $165 million by 2026 |
Strategic partnership opportunities include:
- Potential collaboration with 3 major pharmaceutical research institutions
- International market penetration in 5 new countries
- Digital health technology integration budget: $35 million
Competitive advantages include:
- Patent portfolio: 17 active pharmaceutical patents
- Research and development efficiency ratio: 22% of total revenue
- Intellectual property protection across 4 major global markets
Alkermes plc (ALKS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.